| Members |
targetComponentId |
| Lyophilized powder for conventional release liposomal suspension for injection |
Powder for suspension for injection |
| Lyophilized powder for conventional release solution for infusion |
Powder for conventional release solution for infusion (dose form) |
| Lyophilized powder for conventional release solution for infusion and/or injection |
Powder for conventional release solution for infusion and/or injection (dose form) |
| Lyophilized powder for conventional release solution for injection |
Powder for solution for injection |
| Lyophilized powder for conventional release suspension for injection |
Powder for suspension for injection |
| Lyophilized powder for prolonged-release suspension for injection |
Powder for prolonged-release suspension for injection (dose form) |
| Lypressin allergy |
Allergy to antidiuretic hormone |
| Lysis of adhesions of abdomen |
Lysis of adhesions of peritoneum |
| Lückenschadel |
Craniolacunia |
| M+nage E trois |
Ménage à trois |
| M0 category |
American Joint Committee on Cancer cM0 (qualifier value) |
| M1 (IV): Distant metastasis |
American Joint Committee on Cancer cM1 (qualifier value) |
| M1 (IVB): Distant metastasis |
American Joint Committee on Cancer cM1 (qualifier value) |
| M1 category |
American Joint Committee on Cancer cM1 (qualifier value) |
| M1: Distant metastasis [includes metastasis to ipsilateral supraclavicular lymph nodes] |
American Joint Committee on Cancer cM1 (qualifier value) |
| M1: Distant metastasis, includes separate tumor nodule(s) in a different lobe (ipsilateral or contralateral) |
American Joint Committee on Cancer cM1 (qualifier value) |
| M1a (III): gestational trophoblastic tumor extends to the lungs with or without genital tract involvement |
American Joint Committee on Cancer cM1a (qualifier value) |
| M1a (IIIA): gestational trophoblastic tumor extends to the lungs with or without genital tract involvement without risk factors |
American Joint Committee on Cancer cM1a (qualifier value) |
| M1a (IIIB): gestational trophoblastic tumor extends to the lungs with or without genital tract involvement with one risk factor |
American Joint Committee on Cancer cM1a (qualifier value) |
| M1a (IIIC): gestational trophoblastic tumor extends to the lungs with or without genital tract involvement with two risk factors |
American Joint Committee on Cancer cM1a (qualifier value) |
| M1a: Non-regional lymph node or pulmonary metastasis |
American Joint Committee on Cancer cM1a (qualifier value) |
| M1a: non-regional lymph node metastasis |
American Joint Committee on Cancer cM1a (qualifier value) |
| M1b (IV): All other metastatic sites |
American Joint Committee on Cancer cM1b (qualifier value) |
| M1b (IVA): All other metastatic sites without risk factors |
American Joint Committee on Cancer cM1b (qualifier value) |
| M1b (IVB): All other metastatic sites with one risk factor |
American Joint Committee on Cancer cM1b (qualifier value) |
| M1b (IVC): All other metastatic sites with two risk factors |
American Joint Committee on Cancer cM1b (qualifier value) |
| M1b: Bone(s) |
American Joint Committee on Cancer cM1b (qualifier value) |
| M1b: Distant metastasis other than to non-regional lymph nodes and lungs |
American Joint Committee on Cancer cM1b (qualifier value) |
| M1c: Other site(s) |
cM1c |
| MV |
megavolt (qualifier value) |
| MYH9 macrothrombocytopenia syndrome |
MYH9 related disease |
| Machine tool operator |
Machine-tool operator (general) |
| Mackerel - dietary |
Mackerel (substance) |
| Macrolide overdose |
Macrolide antibacterial overdose (disorder) |
| Madlener operation on fallopian tube |
Ligation and crushing of bilateral fallopian tubes (procedure) |
| Mafenide acetate 5% powder |
Product containing only mafenide (medicinal product) |
| Mafenide acetate 85mg/g conventional release cutaneous cream |
Product containing precisely mafenide (as mafenide acetate) 85 milligram/1 milliliter conventional release cutaneous cream (clinical drug) |
| Mafenide acetate 85mg/g cream |
Product containing precisely mafenide (as mafenide acetate) 85 milligram/1 milliliter conventional release cutaneous cream (clinical drug) |
| Magaldrate 800mg/5mL suspension |
Product containing precisely magaldrate 80 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Magnesium aspartate hydrochloride |
Product containing magnesium aspartate (medicinal product) |
| Magnesium chloride 200mg/mL injection solution ampule |
Product containing only magnesium chloride in parenteral dose form (medicinal product form) |
| Magnesium citrate 17.7g/sachet powder |
Product containing only magnesium citrate (medicinal product) |
| Magnesium salicylate 467mg caplet |
Product containing only magnesium salicylate in oral dose form (medicinal product form) |
| Magnesium salicylate 467mg conventional release oral tablet |
Product containing only magnesium salicylate in oral dose form (medicinal product form) |
| Magnesium salicylate 500mg caplet |
Product containing only magnesium salicylate in oral dose form (medicinal product form) |
| Magnesium salicylate 500mg conventional release oral tablet |
Product containing only magnesium salicylate in oral dose form (medicinal product form) |
| Magnesium supplement |
Magnesium compound |
| Magnesium trisilicate+belladonna 0.15mg tablet |
Belladonna alkaloid and magnesium trisilicate only product |
| Magnesium-based antacid |
Magnesium compound |
| Maintenance of prosthesis in organ NOC |
Attention to device (procedure) |
| Major amblyoscope |
Major amblyoscope (physical object) |
| Major depressive disorder clinical management plan |
Major depressive disorder clinical management plan |
| Major puerperal infection |
Postnatal infection |
| Major salivary gland TNM finding |
American Joint Committee on Cancer allowable value |
| Major thoracotomy with open intrapleural pneumonolysis |
Therapeutic pneumothorax |
| Making obscene telephone calls |
Telephone scatologia |
| Malathion 1% cream shampoo |
Malathion 10 mg/mL shampoo |
| Male erectile disorder |
Erectile dysfunction |
| Male fiancé of subject |
Male fiance |
| Male pelvic peritonitis |
Pelvic peritonitis |
| Maleic anhydrid specific extract |
Maleic anhydride |
| Malignant adenomatous neoplasm - category |
Malignant adenomatous neoplasm (morphologic abnormality) |
| Malignant blood vessel neoplasm, primary |
Malignant blood vessel neoplasm |
| Malignant carcinoid tumor |
Well-differentiated neuroendocrine tumour |
| Malignant carcinoid tumor |
Well-differentiated neuroendocrine tumor (morphologic abnormality) |
| Malignant carcinoid tumor of bronchus |
Carcinoid tumour of bronchus |
| Malignant carcinoid tumor of colon |
Well-differentiated neuroendocrine tumor of colon |
| Malignant carcinoid tumor of kidney |
Well-differentiated neuroendocrine tumor of kidney |
| Malignant carcinoid tumor of rectum |
Well-differentiated neuroendocrine tumour of rectum |
| Malignant carcinoid tumor of sigmoid colon |
Well-differentiated neuroendocrine tumour of sigmoid colon |
| Malignant carcinoid tumor of small intestine |
Well-differentiated neuroendocrine tumor of small intestine (disorder) |
| Malignant carcinoid tumor of stomach |
Well-differentiated neuroendocrine tumour of stomach |
| Malignant carcinoid tumor of thymus |
Well-differentiated neuroendocrine tumour of thymus |
| Malignant epithelial neoplasm - category |
Malignant epithelial neoplasm |
| Malignant fibrohistiocytic neoplasm - category |
Malignant fibrohistiocytic neoplasm (morphologic abnormality) |
| Malignant glioma - category |
Glioma, malignant (morphologic abnormality) |
| Malignant histiocytic neoplasm - category |
Malignant histiocytic neoplasm (morphologic abnormality) |
| Malignant histiocytosis |
Malignant histiocytosis |
| Malignant histiocytosis of extranodal AND/OR solid organ site |
Malignant histiocytosis (clinical) |
| Malignant histiocytosis of lymph nodes of axilla AND/OR upper limb |
Malignant histiocytosis of lymph nodes of upper limb |
| Malignant histiocytosis of lymph nodes of inguinal region AND/OR lower limb |
Malignant histiocytosis of lymph nodes of lower limb (disorder) |
| Malignant histiocytosis of lymph nodes of inguinal region and lower limb |
Malignant histiocytosis of lymph nodes of lower limb (disorder) |
| Malignant hypothermia due to anesthetic |
Hypothermia caused by anesthetic (finding) |
| Malignant lymphangioma |
Lymphangiosarcoma |
| Malignant lymphoma - category |
Malignant lymphoma |
| Malignant lymphoma of lymph nodes of axilla AND/OR upper limb |
Malignant lymphoma of lymph nodes of upper limb (disorder) |
| Malignant lymphoma of lymph nodes of inguinal region AND/OR lower limb |
Malignant lymphoma of lymph nodes of lower limb (disorder) |
| Malignant lymphoma, centroblastic, diffuse |
Diffuse large B cell malignant lymphoma (morphologic abnormality) |
| Malignant lymphoma, centroblastic-centrocytic, diffuse |
Malignant lymphoma, mixed small and large cell, diffuse |
| Malignant lymphoma, centrocytic |
Mantle cell lymphoma |
| Malignant lymphoma, diffuse |
Non-Hodgkin lymphoma |
| Malignant lymphoma, large B-cell, diffuse, no International Classification of Diseases for Oncology subtype |
Diffuse large B cell malignant lymphoma (morphologic abnormality) |
| Malignant lymphoma, large cell, cleaved, diffuse |
Diffuse large B cell malignant lymphoma (morphologic abnormality) |
| Malignant lymphoma, large cell, noncleaved, diffuse |
Diffuse large B cell malignant lymphoma (morphologic abnormality) |
| Malignant lymphoma, lymphoblastic |
Precursor cell lymphoblastic lymphoma |
| Malignant lymphoma, lymphocytic, intermediate differentiation, nodular |
Non-Hodgkin lymphoma |
| Malignant lymphoma, lymphocytic, poorly differentiated, nodular |
Follicular lymphoma, grade 1 |
| Malignant lymphoma, no International Classification of Diseases for Oncology subtype |
Malignant lymphoma |
| Malignant lymphoma, small cell, noncleaved, diffuse |
Non-Hodgkin lymphoma |
| Malignant lymphoma, small cleaved cell, diffuse |
Non-Hodgkin lymphoma |
| Malignant lymphomatous polyposis |
Mantle cell lymphoma |
FHIR